loading

Dear Well-wishers,

With tremendous avidity, I present to you this February 2017 edition of Oviya MedSafe’s newsletter, which is the proud 59th issue of the monthly series I have been writing ever since I founded the brand Oviya MedSafe on 14th March 2012.

Although I thoroughly enjoy the creative journey of synthesizing the newsletter every month with details of Oviya MedSafe’s key organizational milestones, featured drug safety services, selected case studies from our pharmacovigilance consulting portfolio, scientific publications, general information of interest to global as well as regional pharmacovigilance enthusiasts, and above all the narratives of our expeditions beyond business to propagate the science of Drug Safety for the cause of Patient Safety, I earnestly believe that it is the meticulous set of the now 18000+ strong size of our readership that has continuously motivated me to do this throughout these 5 years with the same level of enthusiasm I had when I released the first issue. Quite naturally, this brings us to the focal sub-topic of this newsletter – the forthcoming 5th Anniversary of Oviya MedSafe’s founding.

We at Oviya MedSafe have planned to celebrate our 5th Anniversary by doing what we love the most, namely satiating our deep-rooted desire of enlightening our immediate environment with learnings from our travel in pharmacovigilance so far. For this purpose, Oviya MedSafe has partnered with event management firm VHEO Ventures, to organize DRUG DILIGENCE 2017, a Two Day National Level Conference & Workshop on Pharmacovigilance, at IMA Hall, Coimbatore on 17th & 18th March 2017. The event is open to all responsible stakeholders of Patient Safety, for them to hear, discuss and clarify various aspects of Pharmacovigilance.

The programme has renowned national and local faculty from the academia, pharmaceutical industry, government officials and service providers in pharmacovigilance & related segments. I am enthused to emphasize the fact that The Tamil Nadu Dr MGR Medical University has awarded 20 CME Credit Points under Category III, for DRUG DILIGENCE 2017.

The highlight of the programme is a paper presentation session on pharmacovigilance which is exclusively meant for student delegates. Ten papers will be shortlisted for presentation from the abstracts received in prior and the first three places will be adjudged and awarded by the Guest Speakers.

The brochure along with the delegate registration form for DRUG DILIGENCE 2017 may be downloaded in PDF format from Oviya MedSafe’s downloads page. Alternatively, the JPEG format images of the document may be accessed through my LinkedIn article or Oviya MedSafe’s Facebook post. I request you to kindly consider registering to attend this event and also forward the brochure to any of your friends who may be interested.

The very next week following DRUG DILIGENCE 2017, I will be speaking on the topic “Indian Pharmacovigilance – Where do we stand today?” at “PV Fast Forward” – Technology, Pace, Priority, the annual pharmacovigilance conference of the Drug Information Association (DIA) in India, which is to be held at Mumbai. In this slot, I wish to provide a critical independent review of the governmental initiatives in pharmacovigilance in India. In addition, I have played the role of a Program Committee Member of this annual conference consecutively for the second year, thanks to DIA.

I owe much more gratitude to DIA for entrusting me with the responsibility of ‘Regional Editor, India‘ of Global Forum (the official magazine of DIA) from its April 2017 issue. Although the fact that the position was last held by Late Prof. Ranjit Roy Chaudhury made me a little bit anxious, I have accepted DIA’s invitation as I am confident that your encouragement and support will help me succeed in this role, for India.

Interestingly, I am to publish this February 2017 newsletter from New Delhi where I have been invited to speak on an intriguing topic ‘The Role of Pharmacovigilance in Pharmacoeconomics‘, at the 5th National Conference of Pharmacoeconomics & Outcomes Research organized under the aegis of ISPOR India at the Delhi Pharmaceutical Sciences & Research University on 3rd & 4th March!

While speaking of all these events, it is my duty to update you that the agendas of the UK Pharmacovigilance Day 2017 (London) and the Indian Pharmacovigilance Day 2017 (Hyderabad) conferences which I will be chairing are shaping up quite well.

I look forward to share these conference reports and other updates too through Oviya MedSafe’s March 2017 newsletter (60th issue).

Thanking you for your patient reading,

With thanks & regards,
Dr J Vijay Venkatraman
MBBS, F. Diab., MBA, FPIPA (UK)

Managing Director & CEO,
Oviya MedSafe Pvt Ltd,
Coimbatore, India
Phone: +91-422-2444442

Director,
Oviya MedSafe UK Ltd,
London, UK
Phone: +44-8452-733839

Web: www.oviyamedsafe.com
Mail: info@oviyamedsafe.com
Follow us on: Facebook, Google Plus, LinkedIn & Twitter

News & Events

  • 30

    Jun

    Oviya MedSafe and Pharmacovigilance Days – London Experiences & Hyderabad Expectations

    Continue Reading...
  • 31

    May

    Oviya MedSafe – Certified MedDRA Coders and Pharmacovigilance Torchbearers

    Continue Reading...
  • 30

    Apr

    Oviya MedSafe as an Innovation Strategist in Global Pharmacovigilance

    Continue Reading...
  • 31

    Mar

    Oviya MedSafe – 5 Years in Pharmacovigilance – 60th Newsletter

    Continue Reading...
  • 24

    Mar

    AIIMS Professor inaugurated DRUG DILIGENCE 2017 at Coimbatore

    Continue Reading...
  • 28

    Feb

    Oviya MedSafe – DRUG DILIGENCE 2017 and Honours from DIA & ISPOR

    Continue Reading...
  • 27

    Feb

    Drug Diligence 2017 – 17th & 18th March – Coimbatore

    Continue Reading...
  • 31

    Jan

    Oviya MedSafe – Building Pharmacovigilance Strategies & Invited Article in DIA Global Forum

    Continue Reading...
  • 31

    Dec

    Oviya MedSafe fosters Industry-Academia Partnerships for Pharmacovigilance

    Continue Reading...
  • 30

    Nov

    Oviya MedSafe – Pragmatic Pharmacovigilance Support for US ANDA Holders

    Continue Reading...
View All